Repositioning Candidate Details
| Candidate ID: | R0259 |
| Source ID: | DB00738 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Pentamidine |
| Synonyms: | 1,5-bis(4-amidinophenoxy)pentane; 4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(pentamethylenedioxy)dibenzamidine; 4,4'-Diamidinodiphenoxypentane; p,p'-(pentamethylenedioxy)dibenzamidine |
| Molecular Formula: | C19H24N4O2 |
| SMILES: | NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1 |
| Structure: |
|
| DrugBank Description: | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. |
| CAS Number: | 100-33-4 |
| Molecular Weight: | 340.4195 |
| DrugBank Indication: | For the treatment of pneumonia due to <i>Pneumocystis carinii</i>. |
| DrugBank Pharmacology: | Pentamidine is an antiprotozoal agent. It is an aromatic diamidine, and is known to have activity against <i>Pneumocystis carinii</i>. The exact nature of its antiprotozoal action is unknown. <i>in vitro</i> studies with mammalian tissues and the protozoan <i>Crithidia oncopelti</i> indicate that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids and proteins. Little is known about the drug's pharmacokinetics. The medication is also useful in Leishmaniasis and in prophylaxis against sleeping sickness caused by <i>Trypanosoma brucei gambiense</i>. Hydration before treatment lessens the incidence and severity of side effects, which include liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, hypocalemia, leukopenia, thrombcytopenia, anemia, and allergic reaction. It is generally well-tolerated. |
| DrugBank MoA: | The mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins. |
| Targets: | DNA intercalation; tRNA (cytosine(38)-C(5))-methyltransferase other |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I01 | 552 | Pneumonia | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |